MBL International, a provider of products and solutions for clinical diagnostics, has introduced AngioPhase.
AngioPhase is an angiogenesis kit which is designed for the analysis of all known phases of the angiogenic process in a convenient and flexible format.
Angiogenesis is a multistep process in which new blood vessels develop from pre-existing vasculature and helps in the natural process of healing and reproduction.
It also plays a key role in many pathological processes including cancer, skin diseases, age-related blindness, diabetic ulcers, cardiovascular disease, and stroke.
AngioPhase utilzes a patented technology, developed by TCS Cellworks, in which human endothelial cells are co-cultured with other human cells in a specially designed medium.
MBL been awarded a license to manufacture and sell the assay in North and South America, as per the non-exclusive agreement with TCS Cellworks.
MBL International CEO Dennis Walczewski said this technology provides many benefits to researchers in the biotechnology and pharmaceutical industries by offering a ready-to-use angiogenesis kit in which test compounds can be added at any time.
"Moreover, both angiogenic simulators and inhibitors can be assessed as well as tubule formation," Walczewski said.